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Abstract
Background: Toxoplasmosis causes loss of life, cognitive and motor function, and sight. A vaccine is greatly
needed to prevent this disease. The purpose of this study was to use an immmunosense approach to develop a
foundation for development of vaccines to protect humans with the HLA-A03 supertype. Three peptides had been
identified with high binding scores for HLA-A03 supertypes using bioinformatic algorhythms, high measured
binding affinity for HLA-A03 supertype molecules, and ability to elicit IFN-g production by human HLA-A03
supertype peripheral blood CD8
+ T cells from seropositive but not seronegative persons.
Results: Herein, when these peptides were administered with the universal CD4
+T cell epitope PADRE
(AKFVAAWTLKAAA) and formulated as lipopeptides, or administered with GLA-SE either alone, or with Pam2Cys
added, we found we successfully created preparations that induced IFN-g and reduced parasite burden in HLA-
A*1101(an HLA-A03 supertype allele) transgenic mice. GLA-SE is a novel emulsified synthetic TLR4 ligand that is
known to facilitate development of T Helper 1 cell (TH1) responses. Then, so our peptides would include those
expressed in tachyzoites, bradyzoites and sporozoites from both Type I and II parasites, we used our approaches
which had identified the initial peptides. We identified additional peptides using bioinformatics, binding affinity
assays, and study of responses of HLA-A03 human cells. Lastly, we found that immunization of HLA-A*1101
transgenic mice with all the pooled peptides administered with PADRE, GLA-SE, and Pam2Cys is an effective way
to elicit IFN-g producing CD8
+ splenic T cells and protection. Immunizations included the following peptides
together: KSFKDILPK (SAG1224-232); AMLTAFFLR (GRA6164-172); RSFKDLLKK (GRA7134-142); STFWPCLLR (SAG2C13-21);
SSAYVFSVK(SPA250-258); and AVVSLLRLLK(SPA89-98). This immunization elicited robust protection, measured as reduced
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any medium, provided the original work is properly cited.parasite burden using a luciferase transfected parasite, luciferin, this novel, HLA transgenic mouse model, and
imaging with a Xenogen camera.
Conclusions: Toxoplasma gondii peptides elicit HLA-A03 restricted, IFN-g producing, CD8
+ T cells in humans and
mice. These peptides administered with adjuvants reduce parasite burden in HLA-A*1101 transgenic mice. This
work provides a foundation for immunosense based vaccines. It also defines novel adjuvants for newly identified
peptides for vaccines to prevent toxoplasmosis in those with HLA-A03 supertype alleles.
Background
Toxoplasmosis is a disease of major medical importance.
Toxoplasma gondii causes congenital infections respon-
sible for stillbirths and spontaneous abortions[1-5]. In
addition, it causes neurologic disorders, uveitis, and sys-
temic infections in immune-compromised patients. Tox-
oplasmic encephalitis is a cause of morbidity and
mortality in those with congenital disease and persons
with AIDS[6]. T. gondii is acquired by consumption of
lightly cooked meat, especially lamb and pork contami-
nated with bradyzoites[7,8] or by ingestion of food or
water contaminated with oocysts containing sporozoites,
which are the product of a sexual cycle in the intestine
of the cat [8,9].
Development of an effective vaccine would prevent this
disease. Attenuated T. gondii tachyzoites (e.g., S48, TS-4,
T-203, ΔRPS13)have been employed for live vaccinations
of non-human animals[10-15]. Parasites attenuated by
knockout of gene transcription recently have been pro-
posed as a new type of attenuated vaccine candidate
[13-15]. However, safety considerations may limit vacci-
nation of humans with live organisms. Development of
peptide-based vaccines created with epitopes which elicit
IFN-g production by CD8
+ T cells [16] is a promising
strategy to mobilize the immune system against T. gondii
in humans[16-20]. Thus, an effort to create an immuno-
sense epitope-based vaccine was initiated.
Recently, three peptide epitopes, KSFKDILPK
(SAG1224-232), AMLTAFFLR (GRA6164-172), and RSFKD
LLKK (GRA7134-142), were found by our group to elicit
IFN-g from peripheral blood mononuclear leukocytes
(PBMCs) from T. gondii seropositive HLA-A03 super-
type humans but not from PBMCs of T. gondii serone-
gative HLA-A03 supertype humans[18]. Herein, initially
we designed 4 CD8
+ T cell epitope containing vaccine
formulations comprised of lipopeptides that incorporate
PADRE as well as a novel oil-in-water emulsion that
includes a specially formulated synthetic MLA derivative
called GLA-SE[21-24]. First, efficacy of various vaccine
formulations consisting of the three previously identified
CD8
+ T cell peptides eliciting HLA-A*1101-restricted,
CD8
+T cell-mediated IFN-g production in vitro from
HLA-A*1101 mice was examined.
Then, in order to identify additional peptides from
T. gondii tachyzoites, bradyzoites and sporozoites of
Type I and Type II strains that are effective in eliciting
IFN-g from HLA-A03 supertype restricted CD8
+ T cells,
the first step was to select proteins with biologic proper-
ties, such as being secreted, compatible with MHC Class
I processing. Then, bioinformatic algorithms to identify
HLA-A03 supertype bound peptides were utilized to find
additional, novel T. gondii-derived, potential CD8
+ T cell
eliciting epitopes restricted by the HLA-A03 supertype.
We screened peptides from tachyzoite, bradyzoite and
sporozoite proteins (GRA10, GRA15, SAG2C, SAG2D,
S A G 2 X ,S A G 3 ,S R S 9 ,B S R 4 ,S P A ,M I C )o ft h et y p eI I
T. gondii strain, ME49, searching for those with high
binding scores in a bioinformatic analysis (IC50 <5 0n M )
and then in binding assays. In addition, peripheral blood
mononuclear cells from seropositive and seronegative
persons were tested for response to these peptides using
an IFN-g ELISpot assay. These latter studies were per-
formed to attempt to identify other peptides that would
be promising candidates for inclusion in a multi-epitope,
next generation immunosense vaccine. Then, informa-
tion obtained from testing the first three peptides studied
was used to guide formulation and administration of a
peptide pool. This pool included the first three peptides
identified earlier and tested in the initial experiments
combined with the newly identified peptides that elicited
IFN-g from human HLA-A03 supertype restricted CD8
+
T cells. All the peptides in this pool were tested with a
universal T helper epitope called PADRE and a new,
promising adjuvant called GLA-SE with Pam2Cys in
HLA-A*1101 transgenic mice. Capacity to induce IFN-g
production by spleen CD8
+ T cells, and to protect against
parasite burden following subsequent challenge were
determined. For parasite challenge, a luciferase trans-
fected Type II Prugneaud parasite was administered,
followed by luciferin administration and imaging with a
Xenogen camera system a week later. This allows detec-
tion and quantization of bioluminescent parasites as a
biomarker to assess efficacy of immunizations in
protection.
Results
Construction of CD4-CD8 lipopeptide based candidate
vaccine
Three CD8
+ T cell epitopes had been identified from
T. gondii proteins, based on their significant recognition
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duals[18]. A universal CD4
+ T cell epitope, PADRE
(AKFVAAWTLKAAA), was linked in sequence with the
N-terminal end of each of the three different T. gondii
CD8
+ T cell epitopes: KSFKDILPK (SAG1224-232), AML-
TAFFLR (GRA6164-172), RSFKDLLKK (GRA7134-142).
Also, these three epitopes were linked together with
three alanines as the linker. The N-terminal end of each
resulting CD4-CD8 peptide or polypeptide was extended
by a lysine covalently linked to two molecules of the
palmitic acid moiety. The lipopeptides (Lp) were named
as LpKS9, LpAM9, LpRS9 and LpKS9-AM9-RS9. They
are shown in Figure 1.
Immunogenicity of lipopeptides in HLA-A*1101
transgenic mice
HLA-A*1101 transgenic mice were immunized twice at
intervals of three weeks with lipopeptides which were
administered in PBS. Two weeks after the last immuni-
zation, the spleens were removed from immunized mice
and the ability of splenocytes to produce IFN-g upon sti-
mulation with peptides was analyzed. Transgenic mice
immunized with the three single peptide lipopeptide
vaccines had T cells that produced IFN-g (Figure 2).
The lipopeptide vaccines LpKS9 and LpAM9 stimulated
higher IFN-g production than LpRS9 (Figure 2). How-
ever, LpKS9-AM9-RS9 with three peptide epitopes
linked together did not stimulate strong IFN-g responses
when splenocytes from these mice were exposed to each
of the individual peptides in vitro.O n l yr e s u l t sw i t h
LpKS9(KS9) and LpAM9(AM9) achieved statistical
significance (Figure 2).
Comparison of vaccination with different formulations of
peptides
In order to determine which formulation was most
immunogenic, vaccination with a single peptide or a
mixture of the peptides was compared with linked lipo-
peptide vaccines. Results of a representative experiment
are presented in Figure 3. Mice immunized with a vac-
cine formulated with a single peptide SAG1224-232,K S 9 -
PADRE with the adjuvancy of GLA-SE and Pam2Cys,
elicited IFN-g production (SFC:248 ± 65; mean ± SEM)
four-fold higher (p < 0.01) than mice that received
LpKS9 GLA-SE vaccination (63 ± 17)(Figure 3a). Similar
results, with substantial IFN-g production, were found
when splenocytes from mice immunized with a mixture
of peptides and adjuvants. These results were compared
with IFN-g production by splenocytes from mice immu-
nized with a lipopeptide vaccine constructed with the
three peptides linked together with alanine spacers
LpKS9-AM9-RS9. Significant IFN-g production was only
present with KS9 and AM9 stimulation of spleen cells,
and was much less robust and not significant when the
spleen cells were stimulated by RS9 peptide.
Effects of adjuvant on immunogenicity of pooled peptide
vaccination
To determine whether, and if so how, adjuvants effected
immunogenicity of these peptides, HLA-A*1101 trans-
genic mice were immunized with pools of peptides that
included all of the three peptides (KS9, AM9, RS9)
alone or with varying adjuvants. HLA-A*1101 transgenic
mice were immunized with: (1) CD8
+ epitope peptide
pool, (2) peptide pool plus PADRE, (3) peptide pool
Figure 1 Schematic representation of the synthetic lipopeptide immunogens used in this study. The C-terminal end of a promiscuous
CD4
+ T cell peptide epitope (PADRE) was joined in sequence with the N-terminal end of one of three different T. gondii CD8 T cell epitopes:
SAG1224-232 (A), GRA6164-172 (B); GRA7134-142 (C) or three epitopes linked together (D) with a three alanine linker. The N-terminal end of each
resulting CD4-CD8 peptide was extended by a lysine covalently linked to one molecule of palmitic acid. This results in a four lipopeptides
construct. The abbreviation Lp is used throughout the manuscript whenever the lipopeptide (Lp) has been studied. When there is a mixture of
components or undivided components they are named individually. Sequence of PADRE is AKFVAAWTLKAAA. Structure of Pam2Cys is PAM2KSS.
a = abbreviation for name of protein from which peptide is derived.
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Page 3 of 15Figure 2 HLA-A*1101 mice immunized with lipopeptides. Mice were immunized with lipopeptides: LpKS9, LpAM9, LpRS9 and LpKS9-AM9-
RS9 which were shown in Figure 1. The mice were immunized twice at intervals of three weeks. Ten to fourteen days after the last
immunization, spleen cells were separated from immunized mice and stimulated by appropriate peptides in an ex vivo IFN-g ELISpot assay. Data
presented are averages of three independent replicate experiments. *, P < 0.05; **, P < 0.01.
Figure 3 Lipopeptides vaccine compared with peptide pool vaccine. HLA-A*1101 transgenic mice were immunized either with lipopeptides
or a mixture of peptides plus GLA-SE and Pam2Cys. LpKS9 and KS9/PADRE/GLA-SE/Pam2Cys (Figure 3a), LpKS9-AM9-RS9 and KS9/AM9/RS9/
PADRE/GLA-SE/Pam2Cys (Figure 3b) were used as immunogens. For the lipopeptide immunizations, the mice were vaccinated twice at intervals
of three weeks. For the immunizations containing individual components including the same peptides, the mice were vaccinated three times at
intervals of two weeks. Ten to fourteen days after the last immunization, spleen cells were separated from immunized mice and stimulated by
the appropriate peptide in an ex vivo IFN-g ELISpot assay. Data presented are a representative example from three independent experiments.
*, P < 0.05; **, P < 0.01.
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pool plus PADRE and Pam2Cys emulsified with GLA-
SE. Mice were inoculated three times at intervals of two
weeks. Eleven to fourteen days post immunization,
spleen cells were isolated and exposed to each individual
peptide. A peptide was considered immunogenic if it
induced IFN-g spot formation that was significantly
higher in the immunization group compared with the
group inoculated with PBS. After the immunizations,
only KS9 and AM9 were found to be immunogenic in
HLA-A*1101 transgenic mice, and only when the iniver-
sal CD4
+ helper T cell peptide epitope PADRE was
included. Robust responsesw e r eo b s e r v e dw h e nG L A -
SE was added in the vaccine. Greater responses were eli-
cited when Pam2Cys was used as an adjuvant for some
peptides but did not enhance responses to all of them,
and in fact reduced the effect of some peptides. Figure 4
shows the representative data of IFN-g spot formation
from the four immunization groups which were stimu-
lated by individual peptides.
Vaccination with peptide pools and adjuvants protects
mice against type II parasite challenge
HLA-A*1101 transgenic mice were immunized with
peptide pools plus PADRE and Pam2Cys in GLA-SE
three times at intervals of two weeks. Mice were chal-
lenged 2 weeks after the last immunization. They were
imaged 7 days after they had been challenged with
10,000 Pru (Fluc) using the Xenogen in vivo imaging
system. As shown in Figure 5, numbers of luciferase
expressing parasites in immunized HLA-A*1101 trans-
genic mice were significantly less compared to numbers
of parasites in unimmunized mice. Mean [standard
deviation](median) was 136[253](30) million for nonim-
munized mice versus 5[4](5) million for immunized
mice. With natural log transformed data, means[stan-
dard deviations] were 3.6[1,6] for nonimmunized mice
versus 1.4[.8] for immunized mice. Differences were sig-
nificant (e.g., p < 0.0064, for the pooled experiments,
using natural log transformed data and two-sample t
test).
Identification of new candidate T. gondii specific
HLA-A*1101-restricted epitopes
We initially identified 3 epitopes that provided protec-
tion against parasite challenge. As a next generation vac-
cine that might be even more robust, elicit CD8
+Tc e l l s
that would be effective against all three life cycle stages
and Type I and II genetic types of the parasite, we
sought to identify additional HLA-A11 epitopes to be
used for vaccine development. In order to identify addi-
tional peptides from T. gondii that were present in
tachyzoites, bradyzoites, and sporozoites of Type II
strains for HLA-A03 supertype restricted CD8
+ T cells,
we screened candidate peptides from tachyzoite, brady-
zoite and sporozoite proteins (GRA15, GRA10, SAG2C,
SAG2X, SAG3, SRS9, SPA and MIC) of the Type II
T. gondii strain (Tables 1 and 2). For parsimony in
numbers of peptides utilized, we attempted to include
peptides present in Type I as well as Type II parasite
genetic types. Peripheral blood mononuclear cells from
seropositive T. gondii donors were tested for response
to these peptides by using the IFN-g ELISpot assay.
Pooled peptides were tested initially. Pools 2 and 5 were
significantly different (p < 0.05) from the control (data
not shown). Then the individual peptides were tested
(Figure 6). Three out of 34 epitopes elicited responses
greater than 50 IFN-g SFC from seropositive donors
PBMC, but not from seronegative donors PBMC
(Figure 6). These peptides and the proteins from which
they are derived are: STFWPCLLR (SAG2C13-21);
SSAYVFSVK (SPA250-258); and AVVSLLRLLK (SPA89-98)
adding proteins expressed in sporozoites and bradyzoites
to the peptides selected. All peptides identified herein then
were found to show high binding affinity to three to five
HLA-A03 supertype alleles in the MHC-peptide binding
a s s a y( T a b l e3 ) .T h en u m b e r si nT a b l e3w h i c hi n d i c a t e
high binding affinity are those less than 500 IC50 nM.
They are indicated by bolded font numbers in Table 3.
Vaccination with peptide pools including newly identified
peptides and adjuvants elicits IFN-g and provides more
protection to mice against Type II parasite challenge
Then, HLA-A*1101 transgenic mice were immunized
with peptide pools which included these newly identified
peptides: KSFKDILPK (SAG1224-232); AMLTAFFLR
(GRA6164-172); RSFKDLLKK (GRA7134-142); STFWPCLLR
(SAG2C13-21); SSAYVFSVK (SPA250-258); AVVSLLRLLK
(SPA89-98)p l u sP A D R Ea n dP a m 2Cys in GLA-SE, They
were immunized three times at intervals of two weeks.
Significant IFN-g spot formation responses were
observed in vitro by the cells from immunized mice
exposed to all the peptides except GRA7134-142. Figure 7a
shows the representative data of IFN-g spot formation
from the four immunization groups which were stimu-
lated by individual peptides. The inclusion of the newly
identified peptides thus had potential to enhance immu-
nogenicity in transgenic HLA-A*1101 mice.
Mice were challenged 2 weeks after the last immuniza-
tion. They were imaged five days after they had been chal-
lenged with 10,000 Pru (Fluc) using a Xenogen in vivo
imaging system. As shown in the initial experiment in
Figure 7b, the numbers of luciferase expressing parasites
in immunized HLA-A*1101 mice were significantly
reduced compared to the numbers of parasites in unim-
munized mice. Results were mean[standard deviation]
(median) 2.5[1](2.3) million for nonimmunized mice ver-
sus.6[.3](.5)million for immunized mice. With natural log
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nonimmunized mice versus -.6[.4] for immunized mice;
p < 0.0025 using natural log transformed data and two-
sample t test.
Population Coverage prediction
An algorithm was developed to calculate projected
population coverage of a T cell epitope-based vaccine
using MHC binding or T cell restriction data and HLA
gene frequencies[17]. We used this web-based tool
http://www.iedb.org/ to predict population coverage of
these HLA-A03 supertype peptide epitopes-based vac-
cine. The population coverage calculation results in
Table 4 indicate that such coverage is varied in different
geographic regions. The HLA-A03 supertype molecules
that present these peptides would be expected to be pre-
sent in 28.90% population in Australia; 41.46% in
Europe; 11.29% in North America; 18.86% in North-East
Asia; 37.73% in South-East Asia; 34.29% in South-West
Asia; 34.09% in Oceania; 27.32% in North Africa; 13.14%
in Sub-Saharan Africa and 22.13% for others. The aver-
age population coverage by the HLA-A03 supertype is
24.51% ± 12.06%.
Discussion
In this study, we first evaluated immunization of HLA-
A*1101 transgenic mice with either mixtures of peptides
or lipopeptides derived from three identified T. gondii
specific HLA-A*1101 restricted CD8
+ T cell epitopes
emulsified in 3-deacylated monophosphoryl lipid A
(GLA-SE) adjuvant. Immunizations of transgenic mice
with a mixture of CD8
+ epitope peptide pools plus
PADRE and adjuvants were able to induce splenocyte to
produce IFN-g and to protect against challenge with
high numbers of Type II parasites.
Conjugation of CD8
+ T cell determinants to lipid
groups is known to enhance specific cell-mediated
responses to target antigens in experimental animals and
humans[25-29], although mechanisms whereby immunity
is achieved remains poorly understood. Lipopeptides hold
several advantages over other conventional vaccine for-
mulations; for instance, they are self-adjuvanting and dis-
play none of the toxicity-associated side effects of other
Th1-inducing adjuvant systems. In our work, transgenic
mice that were immunized with three short lipopeptide
vaccines had T cells that produced IFN-g. Among them
the lipopeptide vaccine formulated with KS9 or AM9
Figure 4 HLA-A*1101 transgenic mice immunized with peptide pool and adjuvants. Mice were immunized with PBS, peptide pool,
peptide pool with PADRE, peptide pool with PADRE in GLA-SE, peptide pool with PADRE and Pam2Cys in GLA-SE. Splenic T cells were isolated
10-14 days post-immunization and exposed to each peptide in an ex vivo IFN-g ELISpot assay.
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Page 6 of 15Figure 5 In vivo protection demonstrated with imaging using Xenogen camera. HLA-A*1101 transgenic mice immunized with peptide
pool and adjuvants were protected compared to control mice inoculated with PBS when they were challenged with 10,000 Prugneaud strain
(Fluc)-T. gondii luciferase expressing parasites. There were a total of 5-9(usually 4-5 per group) mice tested in each control or immunization
group. Differences between control and immunization groups were significant(p < 0.0064 using natural log transformed data and two-sample
t test).
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Page 7 of 15Table 1 Peptides, their affinity for HLA-A*1101, and their immunogenicity in humans and for transgenic mice
Peptide Sequences Protein
1 Affinity
2 HLA-A*1101 Elicit IFN-g
3 in Immunogenicity
4 in mice
Seropositive human Seronegative human
KSFKDILPK SAG1224-232 54 + - +
AMLTAFFLR GRA6164-172 3.6 + - +
RSFKDLLKK GRA7134-142 14 + - -
STFWPCLLR SAG2C13-21 10 + - +
SSAYVFSVK SPA250-258 10 + - +
AVVSLLRLLK SPA89-98 34 + - +
1Peptides derived from these proteins and the position within the proteins
2Binding affinity was performed by MHC binding assay.
3PBMC from four T. gondii-seropositive HLA-A03 supertype persons and four seronegative persons were stimulated with peptides, the T cell that produce IFN-g
were tested by ELISpot assay.
4Splenic T cell were isolated from HLA-A*03 supertype(which includes the HLA-A*1101 haplotype) mice 10 to 14 days after peptide immunization and tested for
their ability to generate IFN-g in response to peptide.
Table 2 Predicted peptide candidates utilized for screening CD8+ T cells1
HLA-A*1101 ANTIGEN PEPTIDE SEQUENCES LENGTH LOCATION PREDICTED IC50 nM POOL
HLA-A*1101 GRA15 STSPFATRK 9 152-160 5 P1
HLA-A*1101 GRA15 ASTSPFATRK 10 150-159 18.2
HLA-A*1101 GRA10 AAAATPGLPK 10 568-577 9
HLA-A*1101 GRA10 AAATPGLPK 9 569-577 13.2
HLA-A*1101 GRA10 GVPAVPGLLK 10 507-516 17
HLA-A*1101 GRA10 SVVEENTMAK 10 865-874 25.1
HLA-A*1101 SAG2C STFWPCLLR 9 13-21 9.3 P2
HLA-A*1101 SAG2C ALLDHVFIEK 10 231-240 11.9
HLA-A*1101 SAG2C SSPQNIFYK 9 290-298 12.9
HLA-A*1101 SAG2C STTGVGETGK 10 163-172 28.4
HLA-A*1101 SAG2C GTEYSLALK 9 136-144 35.4
HLA-A*1101 SAG2D SSPQNIFYK 9 122-130 12.9
HLA-A*1101 SAG2D ALLEHVFIEK 10 63-72 20.2 P3
HLA-A*1101 SAG2D SSAQTFFYK 9 290-298 1.8
HLA-A*1101 SAG2D TVYFSCDPK 9 154-162 5.3
HLA-A*1101 SAG2D PSSAQTFFYK 10 289-298 17.9
HLA-A*1101 SAG3 VVGHVTLNK 9 80-88 15.4
HLA-A*1101 SAG3 KQYWYKIEK 9 145-153 19.3
HLA-A*1101 SRS9 TTCSVLVTVK 10 357-366 20.6 P4
HLA-A*1101 SRS9 AAASVQVPLK 10 140-149 29.9
HLA-A*1101 SRS9 AIQSQKWTLK 10 169-178 35
HLA-A*1101 BSR4 TTRFVEIFPK 10 284-293 10.3
HLA-A*1101 BSR4 VSGSLTLSK 9 83-91 21.1
HLA-A*1101 SPA SSAYVFSVK 9 250-258 9.3 P5
HLA-A*1101 SPA TSSAYVFSVK 10 249-258 12.2
HLA-A*1101 SPA YVFSVKELPK 10 253-262 18
HLA-A*1101 SPA KTEATYCYK 9 262-270 18.4
HLA-A*1101 SPA MTLMITRDSK 10 195-204 25.5
HLA-A*1101 SPA AVVSLLRLLK 10 89-98 6.5
HLA-A*1101 SPA VVSLLRLLK 9 90-98 7.2
HLA-A*1101 MIC1 LTLTFISTK 9 338-346 13.8 P6
HLA-A*1101 MIC3 SVQLGSFDK 9 32-40 12.9
HLA-A*1101 MIC4 SAVWFGVAK 9 16-24 17.2
HLA-A*1101 MICA2P GVMTPNQMVK 10 63-72 14.3
1 Peptides derived from GRA10, GRA15, SAG2C, SAG2D, SAG2X, SAG3, SRS9, BSR4, SPA, MIC1, MICA2P were screened for potential supertype epitopes using the
ARB algorithms from immunoepitope database at http://www.iedb.org/ on the basis of their predicted binding affinity to HLA-A*1101. A total of 34 unique
peptides IC50 < 50 nM (lower score, higher predicted binding affinity) of all ranked nonameric or decameric peptides were selected.
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vaccine formulated with RS9. Unexplained and variable
responses have been observed to high affinity binding
peptides in other models, e.g., studies of Livingstone,
Alexander, Sette et al with Lassa fever virus. It will be of
interest to better understand possible mechanisms for
such lack of response in future studies. However, the
lipopeptides with three epitope peptides linked together
with alanine spacers did not stimulate an IFN-g response
by splenocytes from immunized mice when the spleno-
cytes subsequently were exposed to each of the peptides
in vitro. The reason why the lipopeptides with the three
linked peptides did not work well in the transgenic mice
might be related to a frame shift caused by the linkers
that altered the response to the original peptides rather
than the alanines functioning for the intended purpose of
introducing a cleavage motif. The three linker “AAA”
between the peptides had previously been demonstrated
in other systems to result in sensitization to each linked
peptide. However, surprisingly, it did not appear to work
well herein.
Because the three linked peptides in the lipopeptide
formulation were not effective and we had found that a
mixture of the components with a single peptide was as
or more robust than the lipopeptide, we tried this
approach with the three peptides that had been included
in the linked lipopeptide with the universal helper CD4
+
T cell peptide, PADRE, and adjuvants as described
below. The response was robust both in vitro and
in vivo (Figures 4 and 5).
Some studies have shown palmitoylated lipopeptide
constructs to elicit long-lived, protective cellular
responses against a variety of pathogens, including Hepa-
titis B virus (HBV), influenza virus, and Plasmodium fal-
ciparum [25-29]. Our work herein shows that mice
immunized with mixture of CD8
+ and CD4
+ eliciting
peptides and lipid Pam2Cys emulsified in GLA-SE elicited
higher IFN-g production than mice immunized with lipo-
peptides constructed with the same components of CD4
+
and CD8
+ eliciting peptides, and Pam2Cys. The approach
using cocktails of non-covalently linked lipid mixed to
helper T lymphocytes(HTL) and CD8
+T cell (cytolytic T
lymphcyte[CTL] and IFN-g eliciting) epitopes for simul-
taneous induction of multiple CD8
+T specificities would
have significant advantages in terms of ease of vaccine
development.
HTL responses are crucial for the development of
CD8
+T responses, at least in the case of lipidated cova-
lently or non-covalently linked HTL-CTL epitope con-
structs formulated in PBS. Several previous studies have
illustrated a role for CD4
+ responses for development of
CD8
+CTL responses, both in humans and in experimen-
tal animals[30-35]. The inclusion of PADRE, a synthetic
peptide that binds promiscuously to variants of the
Figure 6 New peptides tested with PBMCs from HLA-A03 seropositive and seronegative donors. Then Peripheral blood mononuclear cells
from seropositive T. gondii donors were tested for response to these predicted HLA-A03 supertype restricted CD8
+ T cell epitope individual peptides
by using IFN-g ELISpot assay. Peptides that induced significant IFN-g spot formation compared to DMSO are denoted by an asterisk. *, P <0 . 0 5 .
Table 3 MHC binding affinity assay for peptides that were identified with predictive algorithms for HLA-A03
supertype
HLA-A03-SUPERTYPE
PEPTIDE
SEQUENCE
LENGTH PROTEIN POSITION HLA-
A*0301
HLA-
A*1101
HLA-
A*3001
HLA-
A*3101
HLA-
A*3301
HLA-
A*6801
SUPERTYPE ALLELES
BOUND
STFWPCLLR 9 SAG2C 13-21 22 10 1272 1.2 3.4 0.97 5
SSAYVFSVK 9 SPA 250-258 12 10 1826 97 181 2.1 5
AVVSLLRLLK 10 SPA 89-98 17 34 8.1 1296 1100 94 4
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Page 9 of 15Figure 7 Addition of peptides to pool robustly protects HLA-A*1101 mice against Type II parasite challenge. HLA-A*1101 transgenic
mice were immunized with PBS (controls) or peptide pool with PADRE and Pam2Cys in GLA-SE. Splenic T cells were isolated 10-14 days post
immunization and exposed to each peptide in an ex vivo IFN-g ELISpot assay (Figure 7a). HLA-A*1101 transgenic mice immunized with peptide
pool and adjuvants were protected compared with control mice inoculated with PBS when they were challenged with 10,000 Pru (Fluc)-T. gondii
luciferase expressing parasites (Figure 7b). Mice were immunized and in a subgroup immune function was studied at the same time as the
challenge shown was performed. Differences between control and immunized mice were significant (p < 0.0064 using natural log transformed
data and two-sample t test).
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Page 10 of 15human MHC class II molecule DR and is effective in
mice, also augmented CD8
+ T cell effector functions by
inducing CD4
+ T helper cells[30-35]. Both CD4
+ and
CD8
+ epitopes were targeted in order to drive a protec-
tive immune response[34,35].
Adjuvanting antigens contributes to the success of vacci-
nation. An example herein is that 3-deacylated monopho-
sphoryl lipid A(GLA-SE), a detoxified derivative of the
lipopolysaccharide (LPS) from Salmonella minnesota R595
w a sap o t e n ta d j u v a n t .T h i sG L A - S Ei san o v e la d j u v a n t
which was formulated in an emulsion[21-24]. This is a
Toll-like receptor 4 (TLR4) agonist that is a potent activa-
tor of Th1 responses [21-24]. It has been used as an adju-
vant in human vaccine trials for several infectious disease
and malignancy indications. It has been very effective as
an adjuvant providing CD4
+ T cell help for immunizations
against other protozoan infections such as leishmaniasis
[21-24]. In our study, a robust response was observed
when GLA-SE was included in preparation for immuniza-
tion of mice. Pam2Cys (S-[2,3-bis(palmitoyloxy)propyl]
cysteine) is a lipid component of macrophage-activating
lipopeptide. Pam2Cys binds to and activates dendritic cells
by engagement of Toll-like receptor 2 (TLR-2)[24]. Toll-
like receptors (TLRs) function as pattern-recognition
receptors in mammals[36]. We have found that both
TLR2 and TLR4 receptors participate in human host
defense against T. gondii infection through their activation
by GPIs and GIPLs(Melo, Hargrave, Miller, Blackwell,
Gazinelli, McLeod et al, in preparation, 2010). TLR2 and
TLR4 likely work together with other MyD88-dependent
receptors, including other TLRs, to elicit an effective host
response against T. gondii infection[36]. In our study,
there was a slightly more robust response observed when
Pam2Cys was co-administered for some peptides, but not
all of them.
The goal of the present study was to identify HLA-
restricted epitopes from T. gondii and evaluate whether
they could provide protection against parasite challenge
measured as protection against a luciferase producing
Type ll parasite using a Xenogen camera system. In the
future, additional more detailed studies involving analyses
over longer times, other strains of the parasite and chal-
lenge with life cycle stages, evaluation of multiple organs
including eye and brain, studies of protection in congenital
infections, comparisons of delivery of these peptides as
DNA encoding them versus other formulations. This
future work will follow up and extend these intitial studies
of reduction of parasite burden seen in Figures 5 and 7.
Various peptide-based approaches to induction of
IFN-g responses were evaluated as part of ongoing
efforts to develop immunosense vaccines for use in
humans with each of the supermotifs which would in
total include more that 99% of the human population
worldwide. Robust protection was achieved in the HLA-
A*1101 transgenic mice challenged with Type II para-
sites following immunizations. In order to identify addi-
tional peptides from T. gondii that were present in
tachyzoites or bradyzoites[37,38] or sporozoites of Type
I and II strains and elicited IFN-g from HLA-A03
+
supertype (which includes the HLA*1011 allele)
restricted CD8
+ T cells, bioinformatic algorithms were
utilized to identify novel, T. gondii-derived, epitopes
restricted by the HLA-A03 supertype. Then PBMC cells
were tested to determine whether the peptides elicited
IFN-g from human CD8
+ T cells from seropositive per-
sons. This was intended to collectively provide broad
coverage for the human population with HLA-A03
supertype worldwide. The additional peptides we identi-
fied as immunogenic for human peripheral blood cells
were also robust in eliciting IFN-g from splenocytes of
HLA-A*1101 mice and protection when used to immu-
nize these mice. These findings will facilitate develop-
ment of an immunosense epitope-based vaccine for
human use.
Conclusion
A human immunome-based and parasite genome based
bioinformatices approach was used to define candidate
Table 4 Prediction of population coverage
Class I
Population/Area Coverage
a Average hit
b PC90
c
Australia 28.90% 1.30 0.14
Europe 41.46% 0.98 0.17
North Africa 27.32% 0.45 0.14
North America 11.29% 0.24 0.11
North-East Asia 18.86% 0.74 0.12
Oceania 34.09% 1.69 0.15
Other 22.13% 0.59 0.13
South America 0.42% 0.00 0.10
South-East Asia 37.73% 1.84 0.16
South-West Asia 34.29% 1.09 0.15
Sub-Saharan Africa 13.14% 0.23 0.12
Average (Standard
deviation)
24.51% (12.06%) 0.83 (0.58) 0.14 (0.02)
a projected population coverage for SAG1224-232 (KSFKDILPK); GRA6164-172
(AMLTAFFLR);GRA7134-142 (RSFKDLLKK); SAG2C13-21 (STFWPCLLR); SPA250-
258(SSAYVFSVK); SPA89-98 (AVVSLLRLLK).
b average number of epitope hits/HLA combinations recognized by the
population
c minimum number of epitope hits/HLA combinations recognized by 90% of
the population.
Population coverage was calculated using the analysis resource available at
the IEDB http://www.iedb.org, and as described by Bui et al. 2006 [PMID
16545123]. Calculations are based on HLA genotypic frequencies obtained
from the dbMHC database http://www.ncbi.nlm.nih.gov/mhc/. Population
coverage reflects the fraction of individuals predicted to respond the epitope
set inclusive of SAG1224-232 (KSFKDILPK), GRA6164-172 (AMLTAFFLR),
GRA7134-142 (RSFKDLLKK), SAG2C13-21 (STFWPCLLR), SPA250-258
(SSAYVFSVK), and SPA89-98 (AVVSLLRLLK). The value shown corresponds to
the average coverage across 11 different major geographical areas.
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of a group of T. gondii HLA-A03 supertype restricted pep-
tides, and therefore the proteins from which they are
derived, for immune humans and HLA-A*1101 transgenic
mice was demonstrated. These peptides elicit interferon-g
production by human CD8
+T cells. They also elicit inter-
feron g production by mouse splenocytes when utilized to
immunize HLA-A*1101 transgenic mice with a lipopep-
tide with a universal CD4
+ T cell eliciting epitope,
PADRE, or in peptide pools with PADRE, Pam2Cys and
GLA-SE, a novel adjuvant. Immunization studies demon-
strate the need for and the efficacy of adjuvants in immu-
nization of these HLA transgenic mice. Immunogenic
peptides included KSFKDILPK (SAG1224-232); AML-
TAFFLR (GRA6164-172); and RSFKDLLKK (GRA7134-142);
STFWBCLLR (SAG2C13-21); SSAYVFSVK (SPA250-258);
and AVVSLLRLLK (SPA89-98). The studies herein provide
a foundation for immunosense based vaccines to prevent
toxoplasmosis in those with the HLA-A03 supertype and
information about how they can be adjuvanted.
Methods
Peptides and lipopeptides
HLA-A03 supertype CD8
+ T cell epitopes included:
KSFKDILPK (SAG1224-232), AMLTAFFLR (GRA6164-172),
and RSFKDLLKK (GRA7134-142). PADRE (AKF-
VAAWTLKAAA) was the universal CD4 helper peptide
used in vaccine constructs. Pam2Cys (Pam2-KSS) also was
included. Lipopeptide constructs used in this study are
shown in Figure 1. Peptides and lipopeptides were synthe-
sized by Synthetic Biomolecules, San Diego at > 90% pur-
ity. Additional HLA-A03 supertype bound peptides and
their initial grouping into pools for in vitro studies are
shown in Tables 1 and 2. A TLR4 agonist, a GLA-SE adju-
vant, was synthesized by the Infectious Diseases Research
Institute (Seattle, Washington) as a stable oil-in-water
emulsion. AMLTAFFLR (GRA6 164-172) and additional
new peptides were first dissolved in DMSO and then
diluted in PBS.
Mice
HLA-A*1101/K
b transgenic mice were produced at
Pharmexa-Epimmune (San Diego, CA) and bred at the
University of Chicago. These HLA-A*1101/K
b transgenic
mice express a chimeric gene consisting of the 1 and 2
domains of HLA-A*1101 and the 3 domain of H-2K
b,
and were created on a C57BL/6 background. For each
test, we used 4-5 mice for each group. Each experiment
was repeated 2 to 3 times. Experiments in Figure 7b
were performed including a subgroup analyzed for
immune response in parallel with a subgroup in the
challenge shown. All studies were conducted with
approval of the Institutional Animal Care and Use Com-
mittee at the University of Chicago.
Parasites
Transgenic T. gondii used for in vivo challenges was
derived from Type II Prugniaud (Pru) strain and
expresses the firefly luciferase (FLUC) gene constitu-
tively by tachyzoites and bradyzoites. It was created, and
kindly provided by S. Kim, J. Boothroyd and J. Saeij
(Stanford University) and was maintained and utilized as
previously described[18,37,39].
Immunizations and challenge
To evaluate peptide immunogenicity, HLA-A*1101 trans-
g e n i cm i c ew e r ei n o c u l a t e ds u b c u t a n e o u s l y( s . c . )a tt h e
base of the tail using a 30-gauge needle with single pep-
tides or a mixture of CD8
+ T cell peptides (50 μg of each
peptide per mouse) and PADRE (AKFVAAWTLKAAA)
emulsified in 20 μg of GLA-SE (TLR4 agonist) with or
without Pam2Cys. Pam2Cys concentration was 5 mg/ml.
For immunization with lipopeptides, HLA-A*1101 mice
received 20 nmol lipopeptide dissolved in PBS or emulsi-
fied in GLA-SE. As controls, mice were injected with PBS
or PBS/GLA-SE. For the lipopeptide immunizations, the
mice were vaccinated twice at intervals of three weeks. For
the peptide immunizations, mice were immunized three
times at intervals of two weeks. For challenge studies,
mice were immunized with peptide emulsions and chal-
lenged intraperitoneally (i.p.) 14 days post-immunization
using 10,000 Type II parasites.
In vivo bioluminescence imaging
Mice infected with 10,000 Pru-FLUC tachyzoites were
imaged 7 days post-challenge using the in vivo imaging
system (IVIS; Xenogen, Alameda, CA). Mice were
injected i.p. with 200 μl of D-luciferin, anesthetized in
an O2-rich induction chamber with 2% isoflurane, and
imaged after 12 minutes. Photonic emissions were
assessed using Living image® 2.20.1 software (Xenogen).
Data are presented as pseudocolor representations of
light intensity and mean photons/region of interest
(ROI). All mouse experiments were repeated at least
twice. There were 4-5 mice for each group. In the
experiment in Figure 7b a subgroup of mice was used
for studying immune response in parallel with the sub-
group in the challenge shown.
ELISpot assay
Murine splenocytes
Mice were euthanized 7 to 14 days after immunization.
Spleens were harvested, pressed through a 70 μm screen
to form a single-cell suspension, and depleted of ery-
throcytes with AKC lysis buffer (160 mM NH4Cl,
10 mM KHCO3,1 0 0ME D T A ) .S p l e n o c y t e sw e r e
washed twice with Hank’s Balanced Salt Solution
(HBSS) and resuspended in complete RPMI medium
(RPMI-1640 supplemented with 2 mM L-GlutaMax
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cin, 1 mM sodium pyruvate, 50 M -mercaptoethanol,
and 10% FCS) before they were used in subsequent
in vitro assays. Peptide concentration was 20 mg/ml and
0.20 μl was used per well. ELISpot assays with murine
splenocytes were performed using a-mouse IFN-g mAb
(AN18) and biotinylated a-mouse IFN-g mAb (R4-6A2)
as the cytokine-specific capture antibodies. Antibodies
were monoclonal antibodies. 5 × 10
5 splenocytes were
plated per well.
Human PBMC
PBMC were obtained, HLA haplotype was determined,
and they were processed and cryopreserved as described
[18]. ELISpot assays with human PBMCs were similar to
those with murine splenocytes but used a-human IFN-g
mAb (1-D1K) with biotinylated a-human IFN-g mAb
(7B6-1) with 2 × 10
5 PBMCs per well. All antibodies
and reagents used for ELISpot assays were from Mab-
tech (Cincinnati, OH). Antibodies were monoclonal
antibodies. Both murine and human cells were plated in
at least 3 replicate wells for each condition. Results were
expressed as number of spot forming cells (SFCs) per
10
6 PBMCs or per 10
6 murine splenocytes.
Bioinformatic predictions and MHC-peptide binding
assays
Protein sequences derived from GRA10, GRA15,
SAG2C, SAG2D, SAG2X, SAG3, SRS9, BSR4, SPA, and
MIC were analyzed for CD8
+ T cell epitopes based on
predicted binding affinity to HLA-A03 supertype mole-
cules using ARB algorithms from immunoepitope data-
base (IEDB) http://www.immuneepitope.org[40,41]. A
total of 34 unique peptides IC50 <5 0n Mo fa l lr a n k e d
nonameric peptides were selected. All protein sequences
were from ToxoDB 5.1.
Quantitative assays to measure binding of peptides to
HLA class I molecules are based on inhibition of bind-
ing of radiolabeled standard peptide. Assays were as
described[42]. Concentration of peptide yielding 50%
inhibition of binding of radiolabeled probe peptide
(IC50) was calculated. Under conditions used, where
[radiolabeled probe] < [MHC] and IC50 ≥ [MHC], mea-
sured IC50 values are reasonable approximations of true
Kd values[43,44].
Statistical analyses
Statistical analyses for all in vitro assays were performed
using 2-tailed student’s T test. Natural log transformed
data and two-sample t test were used to analyze data
s h o w ni nF i g u r e s5a n d7 b .T w o - t a i l e dP values < 0.05
were considered statistically significant. Peptides were
considered immunogenic in mice if they induced IFN-g
spot formation from immunized mice that were signifi-
cant (P < 0.05) compared with spot formation from
control mice. All mouse experiments were repeated at
least twice. There were 4-5 mice for each group. The
experiment in Figure 7b determined immune response
and imaged mice in parallel.
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